TBPH vs TECH · P/E 7.5, rev $18.8M vs P/E 65, rev $1.22B
Theravance Biopharma Inc (TBPH) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported TBPH revenue for 2024-12-31 was $18.8M. Net income was -$15.5M. Revenue was up 11.2% from 2024-09-30 to 2024-12-31. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
TBPH currently screens at market cap $861.5M and trailing P/E 7.5. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the TBPH and TECH stock pages for the full models.
Not investment advice.